Daiwa Securities Group
ORIC icon

Daiwa Securities Group’s Oric Pharmaceuticals ORIC Stock Holding History

Daiwa Securities Group’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-249
Closed -$2K – 1365
2025
Q4 		$2K Hold
249
– – ﹤0.01% 1316
2025
Q3 		$3K Hold
249
– – ﹤0.01% 1244
2025
Q2 		$3K Hold
249
– – ﹤0.01% 1195
2025
Q1 		$1K Hold
249
– – ﹤0.01% 1240
2024
Q4 		$2K Hold
249
– – ﹤0.01% 1224
2024
Q3 		$3K Hold
249
– – ﹤0.01% 1201
2024
Q2 		$2K Hold
249
– – ﹤0.01% 1257
2024
Q1 		$3K Buy
+249
New +$2.96K ﹤0.01% 1244
2022
Q4 		– Sell
-135
Closed – – 1362
2022
Q3 		$0 Hold
135
– – ﹤0.01% 1372
2022
Q2 		$1K Hold
135
– – ﹤0.01% 1309
2022
Q1 		$1K Hold
135
– – ﹤0.01% 1323
2021
Q4 		$2K Hold
135
– – ﹤0.01% 1293
2021
Q3 		$3K Buy
135
+66
+96% +$1.34K ﹤0.01% 1221
2021
Q2 		$1K Hold
69
– – ﹤0.01% 1203
2021
Q1 		$2K Hold
69
– – ﹤0.01% 1152
2020
Q4 		$2K Buy
+69
New +$1.98K ﹤0.01% 1130

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Daiwa Securities Group's ORIC Position: Q1 2026 in Review

Daiwa Securities Group sold out of Oric Pharmaceuticals (ORIC) in Q1 2026, closing a stake of 249 shares — an estimated $2K sold.

Daiwa Securities Group first reported a position in ORIC in Q4 2020 and held it in 16 quarters. The position peaked at $3K in Q3 2025. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Daiwa Securities Group reported no remaining Oric Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 249 Oric Pharmaceuticals shares in Q1 2026, an estimated $2K.
  • Daiwa Securities Group first reported a position in Oric Pharmaceuticals in Q4 2020 and held it in 16 quarters.
  • Daiwa Securities Group's Oric Pharmaceuticals position peaked at $3K in Q3 2025.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.